Work

Figure S1 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia

Year: 2023

Type: other

Abstract: Figure S1 shows CD3+ T cells were pre-treated with TAK-981 at the indicated doses for 1 h, followed by TCR stimulation and quantification of western blots of figure 1

DOI: 10.1158/1535-7163.24089570

Authors: Vi Lam, Carly Roleder, Tingting Liu, Nur Bruss, Scott Best, Xiaoguang Wang, Tycel Phillips, Geoffrey Shouse, Allison J. Berger, Lapo Alinari, Lili Wang, Tanya Siddiqi, Nathan D. Pennock, Alexey V. Danilov

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4386485556

Cites:

Cited by:

Related to: 10